



21 October 2013
Company Announcements Office
Australian Stock Exchange Level 6, 20 Bridge Street Sydney NSW 2000

Anteo Diagnostics Releases New Mix&Go™ Based Products for Beta-Testing

- **Anteo has developed and manufactured value added products using its proprietary Mix&Go™ surface coatings**
- **Anteo Mix&Go (AMG™) Beads and Plates to be released for beta testing at AusBiotech Conference in Brisbane**
- **Beta-Testers sought to provide feedback on performance and handling**
- **Launch of commercial products from Anteo planned for Q1 2014**
- **Broadens Anteo's existing product range**

21 October 2013: Anteo Diagnostics Limited (ASX: ADO) ("Anteo") will release for beta-testing two novel products during this year's AusBiotech National Conference in Brisbane. The products are targeted at academic and industry researchers and provide an easy-to-use, high-performance alternative to existing products.

The products to be released for beta-testing are:

- **Anteo Mix&Go (AMG™) Magnetic Beads:** beads coated with Mix&Go and functionalised with streptavidin, a molecule frequently used in research for the specific capture and purification of desired proteins.
- **Anteo Mix&Go (AMG™) Plates:** plates coated with Mix&Go and functionalised with streptavidin. These are used in research to detect and quantify the presence of a desired protein.

The purpose of the beta-test trial is to allow us to work closely with researchers, obtain their feedback on possible improvements in product presentation/documentation and to encourage use in novel areas. Researchers are typically early adopters of new technologies. Demonstrating the utility of Mix&Go in this way will broaden our awareness of the variety of possible applications that would benefit from Mix&Go use in practice.

"Getting feedback from researchers is invaluable to us. It's a great way of learning about new applications for our products that we may not have thought of," says Dr Geoff Cumming, CEO of Anteo. "In addition, taking these two promising products from concept through the whole development cycle and now through beta testing, has allowed us to build and develop skills in QC and manufacturing that the company will benefit from greatly in the future."

Anteo plans the commercial release of these products in Q1 2014.

ENDS

Anteo Diagnostics Limited ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

For More Information Contact:

**Dr Geoff Cumming, CEO
Anteo Diagnostics Limited
Tel: +61 7 3219 0085**

**Sam Sloane
Six Degrees Investor Relations
Tel: +61 2 9230 0661**

For personal use only

***Anteo Diagnostics Limited* ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113**

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com